Company Overview and News


Add ABBV
to your dashboard

Headline News

CELG Stock: Catch This Falling Knife -- Go Long Celgene Corporation | InvestorPlace

23h investorplace
Last night, Celgene Corporation (NASDAQ:CELG) released a headline that they canceled phase three for their potential solution to Crohn’s disease. The stock is now trading down 10%. This means that it would now be down 16% since early October. (351-2)

Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

2017-10-19 zacks
Chicago, IL – October 19, 2017 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: (https://www.zacks.com/stock/news/279133/where-to-find-value-in-healthcare-stocks) (211-0)

4 Large Cap Pharmaceutical Stocks That Could Post Big Earnings

2017-10-19 247wallst
With a market that has become as expensive as this one, there is one key driver that can keep things going, and that’s positive earnings or guidance for the next quarter and 2018. One area that has done well, but has been overshadowed this year by technology is health care, and especially the large cap pharmaceutical companies. While hardly dirt cheap, they offer a defensive posture, dividends and solid growth potential. (133-1)

FDA Approval Of Gilead CAR-T Therapy Will Move The Needle

2017-10-19 seekingalpha
FDA approves Gilead's first CAR-T therapy Yescarta for patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. (93-0)

Abbott Laboratories: Another Strong Quarter From This Dividend Aristocrat

2017-10-18 seekingalpha
Third quarter sales grew by 28.8%, but much of this growth was attributable to acquisitions. On a comparable operational basis, sales growth was still a healthy 5.6%. (161-0)

Antares Pharma: A Company To Keep An Eye On

2017-10-18 seekingalpha
Antares Pharma Inc.’s QuickShot Testosterone (XYOSTED) is awaiting Phase 3 approval by the FDA for treatment of low testosterone levels associated with hypogonadism. (251-0)

Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October

2017-10-18 seekingalpha
Top "safer" dividend Healthcare dog, GSK's 16.2% net gain was 58% more than MRK's 10.4% second place effort, and 100% over PFE's fourth place result per analyst targets 10/13/17. (91-0)

What's in the Cards for Novartis (NVS) This Earnings Season?

2017-10-18 zacks
Swiss pharmaceutical company Novartis AG (NVS - Free Report) is scheduled to report third-quarter 2017 results on Oct 24. (156-0)

Where to Find Value in Healthcare Stocks

2017-10-18 zacks
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. (182-0)

This Pharma Stock Is Up 111% and Investors Are Wondering What's Next - Bloomberg

2017-10-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (96-0)

Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

2017-10-17 zacks
Sanofi, Inc. (SNY - Free Report) and partner Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that a phase II study evaluating its injection Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis met its primary endpoint. (79-0)

J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

2017-10-17 zacks
Johnson & Johnson (JNJ - Free Report) reported better-than-expected third-quarter 2017 results, beating the Zacks Consensus Estimate for both earnings and sales. The drug and consumer products giant raised its 2017 sales and profit outlook, which sent shares up 1.5% in pre-market trading. (81-0)

The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

2017-10-17 zacks
Chicago, IL – October 17, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVie (NYSE: (ABBV - Free Report)  – Free Report), American Express (NYSE: (AXP - Free Report)  – Free Report), Abbott (NYSE: (ABT - Free Report)  – Free Report), United Technologies (NYSE: (UTX - Free Report)  – Free Report) and VMWare (NYSE: (VMW - Free Report)  – Free Report). (178-0)

FFF Portfolio: Nam Tai Takes Off And Adding Qualcomm

2017-10-17 seekingalpha
Welcome back! If you missed the last update to the FFF Portfolio series, you can catch up here. It's only been about a month since we started this series and we've already seen a bunch of movement in the names we hold. In the second update of the FFF Portfolio series I'll give you an overview of where we stand right now, tell you about a recent security I purchased, answer some of your questions from last time, and let you know of some of the future moves I'm considering making. (401-0)

Top Research Reports for AbbVie, American Express & Abbott

2017-10-16 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), American Express (AXP) and Abbott (ABT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (270-0)

AbbVie (ABBV) a Buy on Healthy Earnings Momentum

2017-10-16 investorplace
AbbVie Inc (NYSE:ABBV) is ranked as a Buy using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking ABBV has had from Portfolio Grader for the last month. (67-0)

Is Novo Nordisk Still A Buy?

2017-10-16 seekingalpha
Although it's earnings are less reliable, a new analysis shows it is still trading below its intrinsic value. (74-0)

Biotech Forum Daily Digest: Aratana Therapeutics Back In The Spotlight

2017-10-16 seekingalpha
The biotech sector will try to overcome some late weakness last week as trading opens today. (277-3)

J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use

2017-10-16 zacks
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its plaque psoriasis drug, Stelara for use in adolescents (12 years of age or older). The drug is approved for adults in this indication since 2009. (154-0)

Roche And Allergan: Approaches To Alzheimer's

2017-10-13 seekingalpha
There has been a lot in the press during the past year that pertains to Alzheimer’s disease. While Hillary Clinton’s second presidential campaign made it an issue, new data that is not supportive of formerly viable hypotheses are important. Eli Lilly and Company (LLY) has spent a lot of money attempting to treat Alzheimer’s, since well before Clinton’s candidacy. Similar to other firms, most of Lilly’s effort has been directed at a misfolded protein known as amyloid plaque (Aβ). (204-0)

Spin-Off ETF: Can the Outperformance Continue?

2017-10-13 zacks
Spin-off activities have stepped up lately, with biggies like Honeywell International (HON - Free Report) and Pfizer (PFE - Free Report) being the most active ones. Lately, the industrial giant Honeywell announced plans of spinning off its homes and global distribution units and its transportation systems unit into two publicly traded companies by 2018 end (read: 5 ETFs to Buy on 13-Year High Manufacturing Activity). (89-0)

Cancer Space Update: Lung & Breast Cancer Studies in Focus

2017-10-13 zacks
Major news in the cancer segment this week was the failure of Eli Lilly and Company’s (LLY - Free Report) newly approved breast cancer drug Verzenio in a pivotal lung cancer study. With this latest failure, Lilly joins the list of large pharma companies who have failed in their respective lung cancer pivotal studies in the recent past. However, Verzenio was granted priority review status as first-line treatment for breast cancer. (151-0)

Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

2017-10-13 investorplace
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The lack of a reaction is understandable: Kite may not bring it the growth that it needs. But Gilead’s HCV business is slowing, so management must put its excess cash to good use. Kite could be the company that re-accelerates growth. (119-0)

Glaxo Finds a Rich Vein to Mine With Supercomputers - Bloomberg

2017-10-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (134-0)

The Lower Volatility Stock Portfolio For Retirees And Others

2017-10-12 seekingalpha
I recently had a look at SPDR sectors through the last two major market corrections in search of lower volatility or drawdown. (333-1)

CUSIP: 00287Y959